Titration streptomycin therapy in Meniere's disease: long-term results.
As soon as the use of streptomycin was started for the treatment of tuberculosis, its ototoxic effect was discovered. Initial reports demonstrated that streptomycin was successful in reducing vestibular responses while preserving cochlear activity. Streptomycin sulfate has been used for almost half a century for the treatment of vertigo in patients with Meniere's disease. At the Gruppo Otologico, Piacenza, Italy, between 1987 and 1995 we treated 16 patients with either bilateral Meniere's disease or with Meniere's disease in their only hearing ear, adopting the titration streptomycin therapy protocol of Graham et al. Three patients with follow-up periods of less than 2 years were not included in this study. The ages of the patients ranged from 36 to 64 years with a mean of 49.2 years. The patients were observed for 2 to 8.8 years. The dose of administered streptomycin varied from 14 to 49 gm. Episodic vertigo was totally relieved in all of the patients after initial treatment, whereas hearing remained the same or was improved when compared with the pretreatment levels. Five of the patients experienced recurring vertigo during a period of 4 to 24 months after initial treatment. Oscillopsia persisted in two patients and ataxia in darkness persisted in another two patients. Hearing was unchanged in 14 ears, improved in 2 ears, and worsened in 4 ears at the last follow-up evaluation. The overall outcome indicated that intramuscular titration streptomycin therapy seems to be one of the most important therapeutic options in the treatment of disabling vertigo in patients with either bilateral Meniere's disease or Meniere's disease in an only hearing ear.
Balyan
F R
FR
2nd ENT Clinic of Numune State Hospital, Ankara, Turkey.
Taibah
A
A
De Donato
G
G
Aslan
A
A
Falcioni
M
M
Russo
A
A
Sanna
M
M
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D013307:Streptomycin / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D017186:Titrimetry; D014717:Vertigo / Q000209:etiology
D000900:Anti-Bacterial Agents; D013307:Streptomycin